Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
JETEMA, Co., Ltd. (216080.KQ)
KRW4,605.00
+90.00 (+1.99%)
KR KOE Healthcare Biotechnology
Address
1283-4, Gagok-ri
Wonju, KR
Wonju, KR
CEO
Jeong Sun Nam
Website
jetema.com
IPO
2019-11-14
ISIN KR7216080002
Description
Based in Wonju, South Korea, JETEMA, Co., Ltd. is a dynamic bio-venture firm dedicated to the innovation and development of pharmaceuticals and medical technologies. Their comprehensive portfolio encompasses a range of advanced solutions, including aesthetic treatments such as botulinum toxins, dermal fillers, and specialized anti-aging remedies, along with medical lifting threads. Additionally, they provide laser surgical instruments and hyaluronic acid masks for skincare.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW4,605.00
+90.00 (+1.99%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
321.7K
Beta
0.63
Float Shares
25.69M
Free Float %
71.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.85% | +1.61% | -19.06% | -41.28% | -5.17% | -8.67% | -18.60% | -43.01% | -70.44% | +31.56% | +31.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4,605.00
Ratings Trend (MoM)
| Rating | 2025-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.31
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+12.2% ★ Q1'26: +1.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-3,391.8% Q1'26: +42.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-2.3% Q1'26: -28.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+5.0% ★ Q1'26: -4.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+2.2% ★ Q1'26: -1.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.8% ★ Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×9.51× Q1'26: 20.50× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
20.66B
est: 34.00B (-39.2%)
|
33.22B
est: 55.80B (-40.5%)
|
45.99B
est: 89.20B (-48.4%)
|
58.72B
est: 58.10B (+1.1%)
|
68.52B
est: 65.90B (+4.0%)
|
76.90B
est: 75.30B (+2.1%)
|
90.00B
90.00B – 90.00B
+19.5% YoY
|
109.70B
109.70B – 109.70B
+21.9% YoY
|
| EBITDA |
-5.11B
est: 8.61B (-159.3%)
|
17.93B
est: 14.14B (+26.9%)
|
16.90B
est: 22.60B (-25.2%)
|
22.36B
est: 14.72B (+51.9%)
|
15.48B
est: 22.07B (-29.9%)
|
12.38B
est: 25.22B (-50.9%)
|
30.15B
30.15B – 30.15B
+19.5% YoY
|
36.75B
36.75B – 36.75B
+21.9% YoY
|
| EBIT |
-8.19B
est: 4.31B (-290.0%)
|
14.56B
est: 7.07B (+105.9%)
|
11.97B
est: 11.31B (+5.9%)
|
13.93B
est: 7.36B (+89.2%)
|
6.38B
est: 14.23B (-55.2%)
|
3.82B
est: 16.26B (-76.5%)
|
19.43B
19.43B – 19.43B
+19.5% YoY
|
23.69B
23.69B – 23.69B
+21.9% YoY
|
| Net Income |
-9.33B
est: 5.00B (-286.5%)
|
10.88B
est: 12.99B (-16.2%)
|
1.46B
est: 21.27B (-93.2%)
|
13.97B
est: -12.18B (+214.6%)
|
-188.25M
est: -834.19M (+77.4%)
|
-6.60B
est: -6.91B (+4.5%)
|
1.69B
1.69B – 1.69B
+124.5% YoY
|
5.55B
5.55B – 5.55B
+227.7% YoY
|
| SGA |
8.58B
est: 7.01B (+22.5%)
|
8.27B
est: 11.50B (-28.1%)
|
5.70B
est: 18.39B (-69.0%)
|
7.06B
est: 11.98B (-41.1%)
|
8.38B
est: 9.63B (-13.0%)
|
8.87B
est: 11.00B (-19.4%)
|
13.15B
13.15B – 13.15B
+19.5% YoY
|
16.03B
16.03B – 16.03B
+21.9% YoY
|
| EPS |
-540.96
est: 140.00 (-486.4%)
|
308.00
est: 363.50 (-15.3%)
|
41.00
est: 595.25 (-93.1%)
|
196.00
est: -341.00 (+157.5%)
|
-5.27
est: -23.17 (+77.3%)
|
-184.02
est: -192.00 (+4.2%)
|
47.00
47.00 – 47.00
+124.5% YoY
|
154.00
154.00 – 154.00
+227.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
12.19B
OE per share TTM
339.95
Owner's Yield
5.95%
Maintenance CapEx ratio
8.91%
Maint CapEx / Avg PPE
176.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 4 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 9.1K | 0.46% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 42.3K | 0.29% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 24.4K | 0.39% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 31.0K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
16.82M
Shares Outstanding
35.86M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jae Young Kim | Chief Executive Officer | — | — |
| Jeong Sun Nam | Chief Executive Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 216080.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
